Cannabis and Eczema
Hemp seed oil may help; topical CBD is unproven. Standard treatments remain far more effective.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
The cannabis industry has sold eczema sufferers a lot of CBD creams on the back of a plausible biology story and almost no human trial data. Hemp seed oil works fine as a moisturizer—because it's a bland emollient, not because it's cannabis. Topical corticosteroids, modern biologics like dupilumab, and even plain ceramide creams have decades of evidence behind them. Don't replace proven treatments with marketing.
Not medical advice
This article is for educational purposes and is not medical advice. Eczema has many subtypes and triggers, and severe eczema can become infected or signal other immune issues. If you have moderate-to-severe eczema, talk to a dermatologist before substituting cannabis-derived products for evidence-based treatment. Nothing here should be read as a recommendation to stop prescribed medication.
Plain-language summary
Eczema, most often atopic dermatitis, is a chronic inflammatory skin condition driven by a leaky skin barrier and an overactive type-2 immune response [1]. It itches, it flares, and it's miserable.
Cannabis and hemp products are heavily marketed for eczema, especially CBD creams and hemp seed oil lotions. Here's what the evidence actually shows:
- Hemp seed oil (pressed from cannabis seeds, contains essentially no cannabinoids) is a reasonable emollient. It's high in linoleic and alpha-linolenic acid, and one small randomized crossover trial reported improvement in atopic dermatitis symptoms with dietary hemp seed oil [2]. Weak / limited
- Topical CBD has a plausible biological story—the skin has cannabinoid receptors and the endocannabinoid system regulates inflammation and keratinocyte behavior [3]—but very limited controlled human trial data specifically in eczema. A few small observational studies report symptom improvement, but they lack blinding and control arms [6]. Weak / limited
- Smoking or eating cannabis to treat eczema has no real evidence behind it. No data
- Cannabis itself can cause skin reactions in a minority of users (contact dermatitis, allergic contact urticaria) [4]. Strong evidence
Standard treatments—emollients, topical corticosteroids, topical calcineurin inhibitors, and for severe cases, dupilumab or JAK inhibitors—are far better studied and far more effective [1].
What probably works
Hemp seed oil as a moisturizer. Any bland emollient helps eczema by restoring the skin barrier; this is a cornerstone of guideline-based care [1]. Hemp seed oil is rich in polyunsaturated fatty acids and works as a topical emollient about as well as other plant oils.
A 2005 crossover trial in 20 patients found that 8 weeks of dietary hemp seed oil reduced dryness, itchiness, and topical medication use compared to olive oil [2]. Weak / limited The likely mechanism is straightforward: it supplies fatty acids that support barrier lipids. You do not need cannabinoids for this effect, and you should not pay cannabis-brand prices for what is essentially a seed oil.
What might work
Topical CBD and other cannabinoids. The skin expresses CB1, CB2, and several non-classical cannabinoid-sensitive receptors (TRPV1, PPAR-γ), and endocannabinoids modulate keratinocyte proliferation, sebocyte activity, and immune cell behavior [3]. In vitro and animal studies show that cannabinoids can dampen inflammation and itch signaling [5]. Weak / limited
Human data remains limited. A handful of small open-label and observational reports describe symptom improvement with topical cannabinoid creams in atopic and other dermatoses, but these lack adequate blinding, control arms, or sample sizes [6]. Weak / limited No dose-ranging or vehicle-optimization studies exist in eczema.
PEA (palmitoylethanolamide), a fatty acid amide related to the endocannabinoid system (not from cannabis), has slightly better data. A multicenter study of a PEA-containing cream reported reduced itch and improved skin barrier in atopic dermatitis [7]. Weak / limited PEA is sometimes lumped into 'cannabinoid' marketing, but technically it is an endogenous lipid mediator and does not interact with classical cannabinoid receptors.
Net read: biologically plausible, commercially overhyped, clinically underproven.
What doesn't work or lacks evidence
Smoking or inhaling cannabis to treat eczema. No controlled evidence. Smoke is a known skin irritant and mucosal irritant; inhaled cannabis is associated with worse outcomes in other inflammatory conditions. No data
Oral CBD specifically for eczema. No published randomized controlled trials in atopic dermatitis exist as of October 2026. Generalizing from CBD's anti-inflammatory effects in other settings is insufficient. No data
'Indica vs sativa' for skin conditions. The indica/sativa split does not reliably predict chemistry or effects. There is zero evidence that one 'type' helps eczema more than another. No data
High-THC topicals as a specific eczema treatment. THC has anti-inflammatory effects in lab models, but human eczema data is absent. Topicals also do not produce systemic THC levels meaningful for immune modulation [8]. Weak / limited
What we don't know
- Whether topical CBD at clinically meaningful concentrations outperforms a vehicle cream in a properly blinded randomized controlled trial for atopic dermatitis.
- Whether oral cannabinoids modulate the type-2 immune axis (IL-4, IL-13) enough to matter for eczema patients.
- Optimal concentration, vehicle, or dosing schedule for any topical cannabinoid.
- Whether chronic cannabis use changes eczema trajectory in either direction.
- Interactions between cannabinoids and modern biologics like dupilumab.
- Long-term safety of topical CBD in pediatric eczema.
This is a field where marketing has wildly outrun the science.
Comparison with standard treatments
Standard atopic dermatitis care, per American Academy of Dermatology and EuroGuiDerm guidelines [1]:
- Emollients (daily, including hemp seed oil or ceramide-based creams)—foundation of all treatment. Strong evidence
- Topical corticosteroids—first-line for flares; decades of evidence; potency matched to body site and severity. Strong evidence
- Topical calcineurin inhibitors (tacrolimus, pimecrolimus)—steroid-sparing, particularly useful for face and skin folds. Strong evidence
- Topical JAK inhibitors (ruxolitinib)—newer, effective for flares, expensive. Strong evidence
- Phototherapy (narrowband UVB)—for moderate disease. Strong evidence
- Systemic therapy—dupilumab (anti-IL-4Rα monoclonal antibody), tralokinumab, oral JAK inhibitors for moderate-to-severe disease; these are genuinely transformative for many patients. Strong evidence
No cannabis-derived product has been shown in a high-quality trial to match even mid-potency topical steroids for flare control or to rival modern biologics for disease modification. If a CBD cream helps you and it is not replacing necessary treatment, that is fine. But it is not a substitute for the things that actually work.
Risks and considerations
Cannabis allergy and contact dermatitis. Cannabis sativa contains allergens, notably the non-specific lipid transfer protein Can s 3, that can cause IgE-mediated reactions, contact urticaria, and allergic contact dermatitis [4]. Strong evidence People with eczema already have a compromised skin barrier and are more prone to contact sensitization. Applying a potentially allergenic product to broken skin is a particular concern.
Product quality and contamination. The CBD and hemp topical market is poorly regulated. FDA testing has repeatedly found products that do not match label claims, contain unexpected THC, or are contaminated with heavy metals or pesticides [9]. Applying contaminated products to broken eczematous skin is a hazard.
Drug interactions. Topical absorption of CBD is low, but oral CBD inhibits CYP3A4 and CYP2C19 and can interact with medications including some that treat eczema-related conditions [10]. Strong evidence If you are taking dupilumab, JAK inhibitors, or other systemic therapies, discuss any cannabinoid product with your prescriber.
Cost and opportunity cost. Cannabis-branded skin products are often expensive. The same money spent on a ceramide-based moisturizer (e.g., CeraVe, Eucerin) plus a prescription topical corticosteroid will almost certainly deliver more relief per dollar.
Pediatric use. Eczema commonly affects children. There is essentially no safety data for topical CBD in pediatric eczema. Stick to guideline-based care for children.
Bottom line
Use hemp seed oil as a moisturizer if you like it—it works fine as an emollient. Do not expect topical CBD to do much beyond what its base cream does, and do not pay a premium for it. Do not smoke weed expecting your eczema to improve. See a dermatologist for moderate-to-severe disease; the modern toolkit (especially dupilumab and topical JAK inhibitors) is genuinely effective. The endocannabinoid system in skin is a real and interesting research target, but as of today the consumer market is selling promises the science has not earned.
Sources
- Peer-reviewed Wollenberg A, et al. (2022). European guideline (EuroGuiDerm) on atopic eczema—part I and II. Journal of the European Academy of Dermatology and Venereology, 36(9-10), 1400–1494.
- Peer-reviewed Callaway J, Schwab U, Harvima I, et al. (2005). Efficacy of dietary hempseed oil in patients with atopic dermatitis. Journal of Dermatological Treatment, 16(2), 87–94.
- Peer-reviewed Bíró T, Tóth BI, Haskó G, Paus R, Pacher P (2009). The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends in Pharmacological Sciences, 30(8), 411–420.
- Peer-reviewed Decuyper II, Van Gasse AL, Cop N, et al. (2017). Cannabis sativa allergy: looking through the fog. Allergy, 72(2), 201–206.
- Peer-reviewed Tóth KF, Ádám D, Bíró T, Oláh A (2019). Cannabinoid signaling in the skin: therapeutic potential of the 'c(ut)annabinoid' system. Molecules, 24(5), 918.
- Peer-reviewed Eagleston LRM, Kalani NK, Patel RR, et al. (2018). Cannabinoids in dermatology: a scoping review. Dermatology Online Journal, 24(6).
- Peer-reviewed Eberlein B, Eicke C, Reinhardt HW, Ring J (2008). Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). Journal of the European Academy of Dermatology and Venereology, 22(1), 73–82.
- Peer-reviewed Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR (2004). Human skin permeation of Δ8-tetrahydrocannabinol, cannabidiol and cannabinol. Journal of Pharmacy and Pharmacology, 56(3), 291–297.
- Government U.S. Food and Drug Administration (2021). FDA warning letters and test results for cannabidiol-related products.
- Peer-reviewed Brown JD, Winterstein AG (2019). Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine, 8(7), 989.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Inflammatory Bowel Disease — Cannabis relieves symptoms in IBD but does not heal the bowel or replace standard therapy.
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.